IP Library Granted Patent US 9,534,023
Granted Patent B2
US 9,534,023 · App. 14/845,817 · Granted Jan 3, 2017

Mutated immunoglobulin-binding protein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,534,023
App. No.
14/845,817
Granted
Jan 3, 2017
Kind
B2
Abstract

The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

Claims (18)

1. A matrix for affinity chromatography, comprising a plurality of ligands coupled to a solid support, wherein the ligands comprise an immunoglobulin-binding protein, or multimer thereof, capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), wherein at least the asparagine residue at position 6 or 11 of a parental immunoglobulin-binding protein defined by SEQ ID NO. 1 or 2 has been mutated to an amino acid other than glutamine, which mutation has conferred an increased chemical stability at alkaline pH-values compared to the parental molecule.

2. The matrix of claim 1 , wherein the ligands have been coupled to the support by thioether bonding.

3. The matrix of claim 1 , wherein the support is a natural polymer material.

4. The matrix of claim 1 , wherein the support is a polysaccharide.

5. The matrix of claim 1 , which selectively binds an immunoglobulin selected from the group consisting of IgG, IgA, and IgM.

6. The matrix of claim 5 , which selectively binds an IgG immunoglobulin.

7. The matrix of claim 1 , wherein the ligands exhibit an increased binding capacity, during two or more separations with intermittent alkaline cleaning, compared to the parental protein molecule.

8. The matrix of claim 7 , wherein the cleaning is performed with NaOH and the concentration thereof is up to about 1 M.

9. The matrix of claim 8 , wherein the cleaning is performed with NaOH and the concentration thereof is about 0.5 M.

10. The matrix of claim 1 , wherein the protein is an Fc fragment-binding protein.

11. The matrix of claim 1 , wherein the protein mutation(s) are selected from the group consisting of N6A; N11 S; N11 S and N23T; N6A and N23 T; and N3A, N6D, and N23 T; and wherein the parental molecule comprises the sequence defined by SEQ ID NO. 2.

12. The matrix of claim 1 , wherein the asparagine residue in position 23 has been mutated.

13. The matrix of claim 12 , wherein the asparagine residue in position 23 has been mutated to a threonine residue.

14. The matrix of claim 1 , wherein the ligands include multimers comprising two or more repetitive units of the protein.

15. The matrix of claim 14 , wherein the protein units of the multimers are linked by elements including up to about 15 amino acids.

16. The matrix of claim 14 , wherein the multimers further comprise one or more of the E, D, A, B, and C domains of Staphylococcus protein A.

17. The matrix of claim 14 , wherein the multimers are tetramers.

18. The matrix of claim 14 , wherein each protein unit is the protein defined by SEQ ID NO. 2 and includes the mutation N23T.

Assignments (2)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →